Takayuki Yoshimoto

List of Publications by Year
in descending order

68 papers	3,962 citations	134610 34 h-index	134545 62 g-index
70 all docs	70 docs citations	70 times ranked	5296 citing authors

#	Article	IF	Citations
1	Changes in Expression of Specific mRNA Transcripts after Single- or Re-Irradiation in Mouse Testes. Genes, 2022, 13, 151.	1.0	3
2	A novel coculture system for assessing respiratory sensitizing potential by IL-4 in T cells. ALTEX: Alternatives To Animal Experimentation, 2022, , .	0.9	1
3	Rap1 prevents colitogenic Th17 cell expansion and facilitates Treg cell differentiation and distal TCR signaling. Communications Biology, 2022, 5, 206.	2.0	5
4	Microbial Antigen-Presenting Extracellular Vesicles Derived from Genetically Modified Tumor Cells Promote Antitumor Activity of Dendritic Cells. Pharmaceutics, 2021, 13, 57.	2.0	9
5	IL-23p19 and CD5 antigen-like form a possible novel heterodimeric cytokine and contribute to experimental autoimmune encephalomyelitis development. Scientific Reports, 2021, 11, 5266.	1.6	8
6	Interleukin-1Î² in peripheral monocytes is associated with seizure frequency in pediatric drug-resistant epilepsy. Journal of Neuroimmunology, 2021, 352, 577475.	1.1	15
7	Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report. Journal of Medical Case Reports, 2021, 15, 403.	0.4	5
8	A Chaperone-Like Role for EBI3 in Collaboration With Calnexin Under Inflammatory Conditions. Frontiers in Immunology, 2021, 12, 757669.	2.2	5
9	Adding collagen to adipose tissue transplant increases engraftment by promoting cell proliferation, neovascularisation and macrophage activity in a rat model. International Wound Journal, 2021, , .	1.3	1
10	EBV-induced gene 3 augments IL-23RÎ± protein expression through a chaperone calnexin. Journal of Clinical Investigation, 2020, 130, 6124-6140.	3.9	5
11	Necroptosis of Intestinal Epithelial Cells Induces Type 3 Innate Lymphoid Cell-Dependent Lethal Ileitis. IScience, 2019, 15, 536-551.	1.9	21
12	Plasmacytoid dendritic cells protect against immune-mediated acute liver injury via IL-35. Journal of Clinical Investigation, 2019, 129, 3201-3213.	3.9	27
13	Protective effects against tumors and infection by interleukin-27 through promotion of expansion and differentiation of hematopoietic stem cells into myeloid progenitors. OncoImmunology, 2018, 7, e1421892.	2.1	2
14	Interleukin-27 Exerts Its Antitumor Effects by Promoting Differentiation of Hematopoietic Stem Cells to M1 Macrophages. Cancer Research, 2018, 78, 182-194.	0.4	25
15	Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases. Cellular and Molecular Life Sciences, 2018, 75, 1363-1376.	2.4	68
16	Interleukin (IL)-18, cooperatively with IL-23, induces prominent inflammation and enhances psoriasis-like epidermal hyperplasia. Archives of Dermatological Research, 2017, 309, 315-321.	1.1	24
17	Integrin Î±vÎ²3 enhances the suppressive effect of interferonâ€Î³ on hematopoietic stem cells. EMBO Journal, 2017, 36, 2390-2403.	3.5	28
18	Prediction of Chemical Respiratory and Contact Sensitizers by OX40L Expression in Dendritic Cells Using a Novel 3D Coculture System. Frontiers in Immunology, 2017, 8, 929.	2.2	19

#	Article	IF	Citations
19	Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family. Frontiers in Immunology, 2016, 7, 479.	2.2	107
20	Promotion of Expansion and Differentiation of Hematopoietic Stem Cells by Interleukin-27 into Myeloid Progenitors to Control Infection in Emergency Myelopoiesis. PLoS Pathogens, 2016, 12, e1005507.	2.1	60
21	<scp>IL</scp>â€17Aâ€producing <scp>CD</scp>30⁺ VÎ´1 T cells drive inflammationâ€induced cancer progression. Cancer Science, 2016, 107, 1206-1214.	1.7	28
22	Potential clinical application of interleukinâ€27 as an antitumor agent. Cancer Science, 2015, 106, 1103-1110.	1.7	49
23	Vaccination with OVA-bound nanoparticles encapsulating IL-7 inhibits the growth of OVA-expressing E.G7 tumor cells in vivo. Oncology Reports, 2015, 33, 292-296.	1.2	13
24	Therapeutic potential of interleukin-27 against cancers in preclinical mouse models. OncoImmunology, 2015, 4, e1042200.	2.1	4
25	Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely. Drug Design, Development and Therapy, 2014, 8, 1151.	2.0	17
26	Contribution of IL-12/IL-35 Common Subunit p35 to Maintaining the Testicular Immune Privilege. PLoS ONE, 2014, 9, e96120.	1.1	24
27	Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. OncoImmunology, 2014, 3, e28861.	2.1	11
28	Intratumoral CD4+ T Lymphodepletion Sensitizes Poorly Immunogenic Melanomas to Immunotherapy with an OX40 Agonist. Journal of Investigative Dermatology, 2014, 134, 1884-1892.	0.3	11
29	Interleukin-27: Regulation of Immune Responses and Disease Development by a Pleiotropic Cytokine with Pro- and Anti-inflammatory Properties. , 2014, , 353-375.		0
30	IL-27 promotes nitric oxide production induced by LPS through STAT1, NF-ÎºB and MAPKs. Immunobiology, 2013, 218, 628-634.	0.8	30
31	Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Science, 2013, 104, 1146-1153.	1.7	37
32	IL-27 Enhances the Expression of TRAIL and TLR3 in Human Melanomas and Inhibits Their Tumor Growth in Cooperation with a TLR3 Agonist Poly(I:C) Partly in a TRAIL-Dependent Manner. PLoS ONE, 2013, 8, e76159.	1.1	29
33	Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases. Clinical and Developmental Immunology, 2013, 2013, 1-13.	3.3	132
34	Activation Levels of Natural Killer Cells and CD8+ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients. Blood, 2012, 120, 3745-3745.	0.6	1
35	Regulation of the development of acute hepatitis by ILâ€23 through ILâ€22 and ILâ€17 production. European Journal of Immunology, 2011, 41, 2828-2839.	1.6	36
36	Local expression of interleukinâ€27 ameliorates collagenâ€induced arthritis. Arthritis and Rheumatism, 2011, 63, 2289-2298.	6.7	74

#	Article	IF	Citations
37	Notch signaling drives IL-22 secretion in CD4⁺T cells by stimulating the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5943-5948.	3.3	147
38	A Pivotal Role for Interleukin-27 in CD8⁺T Cell Functions and Generation of Cytotoxic T Lymphocytes. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-10.	3.0	51
39	Antitumor Activities of Interleukin-27 on Melanoma. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2010, 10, 41-46.	0.6	18
40	Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27. Clinical and Developmental Immunology, 2010, 2010, 1-9.	3.3	144
41	Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members. Immunotherapy, 2010, 2, 697-709.	1.0	14
42	Interleukin-27 Activates Natural Killer Cells and Suppresses NK-Resistant Head and Neck Squamous Cell Carcinoma through Inducing Antibody-Dependent Cellular Cytotoxicity. Cancer Research, 2009, 69, 2523-2530.	0.4	95
43	Interleukins and cancer immunotherapy. Immunotherapy, 2009, 1, 825-844.	1.0	26
44	TGF-Î² is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochemical and Biophysical Research Communications, 2009, 386, 105-110.	1.0	68
45	Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Molecular Immunology, 2009, 46, 1654-1662.	1.0	47
46	Antiproliferative Activity of IL-27 on Melanoma. Journal of Immunology, 2008, 180, 6527-6535.	0.4	122
47	STAT3 Is Indispensable to IL-27-Mediated Cell Proliferation but Not to IL-27-Induced Th1 Differentiation and Suppression of Proinflammatory Cytokine Production. Journal of Immunology, 2008, 180, 2903-2911.	0.4	68
48	Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood, 2008, 111, 1903-1912.	0.6	78
49	IL-27 Suppresses Th2 Cell Development and Th2 Cytokines Production from Polarized Th2 Cells: A Novel Therapeutic Way for Th2-Mediated Allergic Inflammation. Journal of Immunology, 2007, 179, 4415-4423.	0.4	180
50	IL-23 Enhances Host Defense against Vaccinia Virus Infection Via a Mechanism Partly Involving IL-17. Journal of Immunology, 2007, 179, 3917-3925.	0.4	50
51	Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. Journal of Bone and Mineral Metabolism, 2007, 25, 277-285.	1.3	80
52	Alternatively activated macrophages express the IL-27 receptor alpha chain WSX-1. Immunobiology, 2006, 211, 427-436.	0.8	58
53	IL-27 Suppresses CD28-Medicated IL-2 Production through Suppressor of Cytokine Signaling 3. Journal of Immunology, 2006, 176, 2773-2780.	0.4	132
54	Interleukin-23 and Interleukin-27 Exert Quite Different Antitumor and Vaccine Effects on Poorly Immunogenic Melanoma. Cancer Research, 2006, 66, 6395-6404.	0.4	135

#	Article	IF	Citations
55	Antiangiogenic and Antitumor Activities of IL-27. Journal of Immunology, 2006, 176, 7317-7324.	0.4	161
56	IL-27 Induces Th1 Differentiation via p38 MAPK/T-bet- and Intercellular Adhesion Molecule-1/LFA-1/ERK1/2-Dependent Pathways. Journal of Immunology, 2006, 177, 7579-7587.	0.4	106
57	A Role for IL-27 in Early Regulation of Th1 Differentiation. Journal of Immunology, 2005, 175, 2191-2200.	0.4	170
58	Augmentation of Effector CD8+ T Cell Generation with Enhanced Granzyme B Expression by IL-27. Journal of Immunology, 2005, 175, 1686-1693.	0.4	162
59	No inhibition of IL-27 signaling by soluble gp130. Biochemical and Biophysical Research Communications, 2005, 326, 724-728.	1.0	58
60	An Indispensable Role for STAT1 in IL-27-Induced T-bet Expression but Not Proliferation of Naive CD4+ T Cells. Journal of Immunology, 2004, 173, 3871-3877.	0.4	196
61	Induction of IgG2a Class Switching in B Cells by IL-27. Journal of Immunology, 2004, 173, 2479-2485.	0.4	125
62	Adjuvant Activities of Novel Cytokines, Interleukin-23 (IL-23) and IL-27, for Induction of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A*0201 Transgenic Mice. Journal of Virology, 2004, 78, 9093-9104.	1.5	76
63	Potent Antitumor Activity of Interleukin-27. Cancer Research, 2004, 64, 1152-1156.	0.4	225
64	Positive Modulation of IL-12 Signaling by Sphingosine Kinase 2 Associating with the IL-12 Receptor Î²1 Cytoplasmic Region. Journal of Immunology, 2003, 171, 1352-1359.	0.4	66
65	A Critical Role of Fc Receptor-Mediated Antibody-Dependent Phagocytosis in the Host Resistance to Blood-Stage Plasmodium berghei XAT Infection. Journal of Immunology, 2001, 166, 6236-6241.	0.4	64
66	Gamma Interferon Production Is Critical for Protective Immunity to Infection with Blood-StagePlasmodium bergheiXAT but Neither NO Production nor NK Cell Activation Is Critical. Infection and Immunity, 1999, 67, 2349-2356.	1.0	76
67	Interleukinâ€12â€Dependent Mechanisms in the Clearance of Bloodâ€Stage Murine Malaria ParasitePlasmodium bergheiXAT, an Attenuated Variant ofP. bergheiNK65. Journal of Infectious Diseases, 1998, 177, 1674-1681.	1.9	30
68	CD40 Ligand Rescues Inhibitor of Differentiation 3-Mediated G1Arrest Induced by Anti-IgM in WEHI-231 B Lymphoma Cells. Journal of the Royal Society of Medicine, 1923, 16, 2453-2461.	0.1	0